In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.

Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.

Inclusion Criteria:

• Laboratory finding of hyperuricemia
• Patients between ages of 18 and 60 years
• Non-diabetic patients
• Creatinine clearance values between 20 and 60 mL/min/1.73 m2

Exclusion Criteria:

• Low (< 20 ml/min/1.73 m2) creatinine clearance,
• Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
• Patients taking urate lowering medication (allopurinol and probenecid)